[Vinpotropile in the treatment of cerebral vascular diseases].
Filimonov
V A
VA
Kliueva
V N
VN
Kondrasheva
I N
IN
D000284:Administration, Oral; D000328:Adult; D001783:Blood Flow Velocity / Q000187:drug effects; D002121:Calcium Channel Blockers; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010889:Piracetam / Q000008:administration & dosage / Q000627:therapeutic use*; D010992:Plethysmography, Impedance; D016896:Treatment Outcome; D017585:Ultrasonography, Doppler, Transcranial; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D004338:Drug Combinations; D018697:Nootropic Agents; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C013983:vinpocetine; D010889:Piracetam